PledPharma has an innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments does not exist.
The company’s most advanced project PledOx® reduces nerve damage associated with chemotherapy. A global phase III program was initiated in November 2018.
The drug candidate Aladote® is developed to prevent acute liver failure associated with acetaminophen/paracetamol poisoning.
PledPharma (STO:PLED) is listed on Nasdaq First North.
- protects the peripheral nerves
Protection against the nerve damage that often occurs in connection with chemotherapy.
- protects the liver
Prevents acute liver failure in paracetamol poisoning.